Sarbanes-Oxley Act

In 2010, a lessening of the regulatory burden on biotech startups looks promising.

We have used the biological processes of microorganisms for 6,000 years to make useful food products, such as bread and cheese, and to preserve dairy products.

July 26 2012
Jeffrey S. Hatfield, President and Chief Executive Officer of Vitae Pharmaceuticals, testified on behalf of BIO about the 10th anniversary of the Sarbanes-Oxley Act.
June 21 2010
BIO supports the coverage gap discount program and believes that it will increase patient access to life-saving and life enhancing therapies BIO provides comments on how the agreement could be modified to ensure the success of the program.
BIO advocated for a provision in financial services reform that would ease regulatory burdens for small public biotechnology companies.
June 29 2011
“Unleashing the Promise of Biotechnology: Advancing American Innovation to Cure Disease and Save Lives” Provides Roadmap for Transformative Policy Changes
December 11 2009
BIO commends the House of Representatives for including provisions intended to ease small business regulatory burdens as part of the Wall Street Reform and Consumer Protection Act of 2009 (H.R. 4173) which passed today.
December 12 2007
An Objective Definition of Small Company in Sarbanes-Oxley Rules Would Lessen the Compliance Burden on Small Biotechnology Firms
July 25 2007
Jim Greenwood released the following statement following a vote today by the U.S. Securities and Exchange Commission’s (SEC) to approve the Public Company Accounting Oversight Board's (PCAOB) proposed auditing reforms to the Sarbanes-Oxley Act (SOX).